Suminobu Ito 研究室

AI 要約（直近 5 年の研究成果）

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

研究成果（8 件）

• [2025] Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan
  DOI: https://doi.org/10.1016/j.vaccine.2025.126754
• [2024] Adverse reactions to mRNA COVID-19 vaccine in people with allergies in Japan
  DOI: https://doi.org/10.35772/ghm.2024.01053
• [2024] A 12-month General Investigation after the Primary Series of COVID-19 Vaccination with Pfizer's vaccine in Hospital Workers who were Vaccinated in the Early Phase after the Regulatory Approval
  DOI: https://doi.org/10.11150/kansenshogakuzasshi.e24002
• [2024] Effects of the induction of humoral and cellular immunity by third vaccination for SARS-CoV-2
  DOI: https://doi.org/10.1016/j.jiac.2024.03.021
• [2023] A disease-specific iPS cell resource for studying rare and intractable diseases
  DOI: https://doi.org/10.1186/s41232-023-00294-2
• [2023] Augmenting Granzyme B–Expressing NK Cells by Invariant NKT Ligand–Loaded APCs in Patients with Postoperative Early Stage Non–Small Cell Lung Cancer: Results of a Randomized Phase II Study
  DOI: https://doi.org/10.4049/immunohorizons.2200091
• [2022] 2 ．Large Scale Cohort Study in Practice
  DOI: https://doi.org/10.3820/jjpe.27.71
• [2022] Reactogenicity and immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 among healthcare workers in Japan: a prospective observational study
  DOI: https://doi.org/10.1080/14760584.2022.2093722

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。